09:27 AM EDT, 06/02/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday that French pharmaceutical company Sanofi ( SNY ) has exercised its option to exclusively license Nurix's STAT6 program.

The license includes drug candidate NX-3911, which is a STAT6 degrader intended to treat inflammation in allergic conditions.

Under the terms of the agreement, Nurix will earn a $15 million license extension fee from Sanofi ( SNY ) under the companies' 2019 collaboration deal. It is also eligible for an additional $465 million in development, regulatory, and commercial milestones associated with the STAT6 program.

The deal also includes potential future royalties and an option to co-develop and co-promote in the US.